Dydrotone Dosage/Direction for Use

Dosages, treatment schedule and duration of treatment may be adapted to the severity of the dysfunction and the clinical response.
Dysfunctional uterine bleeding: When treatment is started to arrest a bleeding episode 10 mg b.i.d. (twice a day) for (5) five to (7) seven days.
For continuous treatment, 10 mg twice a day from day 11 to day 25 of the cycle.
Withdrawal bleeding occurs if the endometrium has been adequately primed with either endogenous or exogenous estrogen.
Secondary amenorrhoea: 10 mg b.i.d. (twice a day) from day 11 to 25 to produce an optimum secretory transformation of an endometrium that has been adequately primed with either endogenous or exogenous estrogen.
Pre-menstrual syndrome: 10 mg b.i.d. (twice a day) from day 12 to 26 of the cycle. The dosage may be increased if necessary.
Endometriosis: 10 mg b.i.d. (twice a day) times daily from day 5 to 25 of the cycle, or continuously.
Dysmenorrhoea: 10 mg b.i.d. (twice a day) from day 5 to 25 of the cycle.
Irregular cycles: 10 mg twice a day from day 11 to 25 of the cycle.
Infertility due to luteal insufficiency: 10 mg b.i.d. (twice a day) from 11 to 25 of the cycle. Treatment should be maintained for at least three consecutive cycles.
Hormone replacement therapy: The standard dose is 10 mg daily for the 14 days of each 28-day estrogen treatment cycle. The dose may be increased to 10 mg twice daily if either early withdrawal bleeding occurs, or if endometrial biopsy reveals inadequate progestational response.
In women who are not taking hormone replacement therapy, have established amenorrhoea or women who switch from a continuous combined hormone replacement therapy, treatment may be started on any convenient day. In women transferring from a cyclic or continuous sequential HRT regimen, treatment should begin the day following completion of the prior regimen. progestational If the patient is menstruating, treatment is started within five days of the start of bleeding.
Method of administration: Oral.